Precision medicine in inflammatory bowel disease
Z Zeng, M Jiang, X Li, J Yuan… - Precision Clinical …, 2023 - academic.oup.com
Inflammatory bowel disease (IBD) is an incurable disease characterized by remission-
relapse cycles throughout its course. Both Crohn's disease (CD) and ulcerative colitis (UC) …
relapse cycles throughout its course. Both Crohn's disease (CD) and ulcerative colitis (UC) …
Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
Z Zeng, H Lin, M Jiang, J Yuan, X Li, Y Jia… - Frontiers in …, 2024 - frontiersin.org
The introduction of anti-tumor necrosis factor α (TNFα) biologics significantly innovated
inflammatory bowel disease (IBD) treatment and increased medical costs. The recent …
inflammatory bowel disease (IBD) treatment and increased medical costs. The recent …
Serum Albumin and Its Trajectory Are Associated with Therapeutic Outcomes in Ulcerative Colitis
J Zheng, X Zhang, L Zhang, L Li, M Chen… - Clinical …, 2024 - Elsevier
Background and aims The relationship between serum albumin levels and therapeutic
outcomes in ulcerative colitis (UC) has been debated. Additionally, the dynamic changes in …
outcomes in ulcerative colitis (UC) has been debated. Additionally, the dynamic changes in …
[HTML][HTML] Treatment endpoints in ulcerative colitis: Does one size fit all?
N Mitrev, V Kariyawasam - World Journal of Gastrointestinal …, 2024 - ncbi.nlm.nih.gov
A treat-to-target strategy in inflammatory bowel disease (IBD) involves treatment
intensification in order to achieve a pre-determined endpoint. Such uniform and tight …
intensification in order to achieve a pre-determined endpoint. Such uniform and tight …